Differential diagnosis of malignant brain tumors

Currently, malignant brain tumors of various types are diagnosed using such visualization methods as magnetic resonance imaging, electroencephalography, positron emission tomography, brain biopsy, which have a number of disadvantages, such as inaccuracy and invasiveness, entailing certain risks to the patient's health. In this regard, the search for more reliable and safe methods for diagnosing gliomas, including the search for biomarkers of this type of cancer in the blood, remains relevant in modern science. Numerous studies indicate changes in the content of circulating DNA in the blood in various types of cancer, including brain cancer. Thus, the study is aimed at qualitative and quantitative determination of DNA decay products in the blood serum of patients with different types of malignant brain tumors. In the course of the work, we had found that the blood plasma of both healthy volunteers and patients with malignant brain tumors (MBT) contain DNA decay products. Quantitative determination of the content of these substances by IR spectroscopy showed a decrease in the content of purine bases in the blood plasma solution of patients with MBT. Visualization of the IR spectra of blood plasma of patients with glioblastoma and anaplastic astrocytoma made it possible to differentiate these tumors from each other.